🇺🇸

Index Intelligence

· daily

Nasdaq 100 Stocks SEC Filings — March 10, 2026

Across the four NASDAQ-100 stream filings dated March 10, 2026, overarching themes include revenue pressures in real estate and coffee segments contrasted by resource expansion and M&A catalysts. CMCT reported 6.3% YoY revenue decline to $116.7M with net loss widening 53.7% to $39.6M due to segment declines and impairments, while KDP Coffee saw flat 1% YoY sales growth to $4.7B, net income down 5% to $700M, but OCF surged 37% to $629M ahead of Q2 2026 spin-off. LBSR aggressively expanded with 13 new claims adding 11.18 sq mi (total footprint +55% to 31.49 sq mi) in Arizona's copper belt, signaling critical minerals upside. Putnam's DEF 14A is routine governance with April 17 AGM. Portfolio trends show mixed sentiment (2/4 mixed, 1 positive, 1 neutral), average materiality 7.5/10, with asset declines at CMCT (-3.4% to $859.2M) vs capex growth at KDP (PPE +9% to $944M). Implications: Avoid overexposed REITs amid margin squeezes, favor mining explorers and M&A plays for alpha amid softening revenues averaging -2.6% YoY where declining.

3 high priority 1 medium 4 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 10, 2026

Across 50 SEC filings from March 10, 2026, primarily non-DJ30 but blue-chip adjacent names show mixed performance with robust revenue growth in defense/security (e.g., Cadre +7.6% YoY sales, AeroVironment +143% Q3) and education retail (Barnes & Noble +11.3% Q3), offset by declines in retail (Kohl's -4% FY), chemicals (Valhi FY loss $57.6M vs profit), and biotechs (Artiva loss +28% YoY). Period-over-period trends reveal 12/20 earnings reporters with YoY revenue growth averaging +25% (outliers Aero +143%, Evolv +40%), but margin compression in 8/15 (avg -100bps, e.g., Aero 38% to 24%) and net losses widening in 10/20 (avg +50%). M&A activity surges with 5 approvals/deals (Alexander & Baldwin 99% vote, York Space shares issued), while banks emphasize governance (M&T CET1 10.84%, US Bancorp new Tech Committee). Forward guidance optimistic in growth names (Cadre +22% 2026 sales), but risks from regulatory (Elevance CMS sanctions Mar 31) and distress (Nine Energy bankruptcy confirmed). Capital allocation favors dividends (Cadre +5.3%, Kohl's $0.125) over buybacks; proxy season ramps with 10+ AGMs in April. Portfolio implication: overweight defense/M&A plays, underweight cyclicals amid mixed sentiment (22 mixed, 10 positive).

19 high priority 31 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 10, 2026

Across 44 SEC filings from the S&P 500 Consumer Discretionary stream (broadly including retail, distribution, leisure, and adjacent financials), mixed sentiment prevails with 70% of financial reporters showing 'mixed' ratings, reflecting revenue growth in high-performers (avg +25% YoY in WLFC 28%, Westrock 40%, TWFG 22%) offset by sales declines in distributors (UNFI -2.6% YoY Q2/Q3). Margin trends diverge: EBITDA expansions (UNFI +23% Q2, WLFC Adj EBITDA +17%) amid op ex cuts, but gross margin compressions (Westrock -560bps to 12.7%, Ultralife impairments) signal scaling costs. Critical developments include M&A (York-Orbion merger, Ashford $95M hotel sale/debt paydown, Infinity Antero acquisition), exec changes (Xponential/SolarEdge CFO departures, Prudential CEO-to-Chairman), and resilient guidance (UNFI raises FY26 EBITDA to $680-710M despite sales cut; Westrock 2026 EBITDA $90-100M +29-44%). Portfolio-level patterns show capital allocation prioritizing debt reduction (Ashford -2.6% indebtedness, UNFI net leverage to 2.3x) and shareholder returns (Enbridge 3% div hike, 31st year; CCEP share repurchases). Consumer spending softness in retail/food distribution contrasts leasing/production strength, implying selective opportunities in growth niches amid macro caution.

26 high priority 18 medium 44 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 10, 2026

Across 33 filings in the USA S&P 500 Healthcare intelligence stream (with extraneous cross-sector inclusions), healthcare firms show mixed performance: managed care leaders like Elevance Health and Centene reaffirmed FY2026 EPS guidance ($25.50+ and >$3.00 adj) despite regulatory headwinds, while biotechs like Lipocine (-82% YoY revenue to $2.0M), Medicinova (+8.6% net loss to $12.0M), and Skye Bioscience (+110% net loss to $55.9M) highlight R&D burn and pipeline risks. Period-over-period trends reveal revenue declines averaging -25% YoY in reporting biotechs/pharma (e.g., Lipocine -82%, CVG proxy -10.3% but non-health), offset by positive trial data (Citius 24% ORR) and leadership stability. No widespread insider trading activity noted, but capital allocation leans defensive with Centene's $1B note redemption and News Corp/Coke buybacks (non-core). Forward-looking catalysts cluster in Q2 2026 (Lipocine NDA, Skye Phase 2b). Portfolio-level: 7/12 core healthcare filings mixed sentiment, margin compression in ops-heavy (e.g., ACRES NII -19% YoY), signaling caution amid regulatory (CMS sanctions March 31) and clinical risks, but opportunities in undervalued pipelines.

19 high priority 14 medium 33 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 09, 2026

Across the 50 filings in the USA S&P 500 Consumer Staples intelligence stream (though spanning diverse sectors including logistics, biotech, SPACs, and select staples-adjacent like Kronos TiO2 for coatings/paper), sentiment is predominantly mixed (12/50), with revenue growth in 7/12 reporting companies averaging +24% YoY (e.g., FuelCell +61%, Myomo +26%, Amex GBT +12% FY) offset by widespread margin compression averaging -143 bps (e.g., Amex GBT -243 bps Q4, Myomo -550 bps FY) and impairments/losses (Kronos FY loss swing, ULH $124M impairment). Period-over-period trends reveal top-line resilience in services/biotech amid cost pressures, with 5/8 companies showing gross margin declines despite volume/AUR gains (Signet SSS +1.2% FY but promotions hit margins). Capital allocation leans shareholder-friendly with $100M+ buybacks (Kimbell, Amex GBT doubled to $600M) and steady dividends (Ellington $0.08/share), while financings exceed $500M (Korro $85M PIPE, OPAL $180M). Insider activity is sparse but stable (lululemon activist holds 8.4%), no major sells flagged. Forward-looking catalysts cluster in Q1-Q2 2026 (Myomo rev guidance $43-46M, annual meetings April, Relmada Phase 3 mid-2026), signaling near-term volatility but growth potential in resilient segments. Portfolio implication: Favor cos with strong guidance/backlogs (Korn Ferry +11% remaining fees) over impairment-heavy names (ULH, Kronos).

25 high priority 25 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 09, 2026

Across the 50 filings in the USA S&P 500 Industrials intelligence stream (despite heavy biotech/pharma overlap), overarching themes include robust revenue growth in select industrials and biotechs (avg +18% YoY across 20+ with data) offset by widespread net loss expansion (avg +60% YoY in 15 cos) due to surging R&D/SG&A expenses (up 50-200% in multiple cases). Period-over-period trends show margin compression in 8/15 reporting cos (avg -150bps), but strong backlogs (+33% YoY Voyager), guidance raises (Voyager +35-53%), and capital raises extending runways to 2028 in 7 cos. Critical developments: Defense/space growth (Voyager Q4 sales +24% YoY), construction outperformance (GLDD rev +16.5%, NI +28.4%), frequent M&A/acquisitions (5 in Voyager), and dense 2026 catalysts (FDA updates, trial data). Portfolio-level patterns reveal biotech-heavy mix with industrials shining on ops metrics; capital allocation favors raises/dividends over buybacks. Market implications: Tactical buys in guided growth names, caution on loss-makers amid high burn; alpha from catalysts in H1-H2 2026.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 09, 2026

Across five SEC 8-K filings in the USA S&P 500 Energy stream (primarily oil/gas refining/production with outliers HOFT/HNRG), dominant themes include proactive debt management via tenders and issuances (OXY, VLO totaling ~$2B in activity) and board enhancements with experienced appointees (PSX, HNRG), signaling governance upgrades amid energy transition. No period-over-period financial trends (YoY/QoQ revenue, margins) or operational metrics reported in these event-driven 8-Ks, but debt actions imply balance sheet optimization potentially lowering interest costs (e.g., OXY retiring high-coupon notes like 6.625%). Sentiments skew positive/mixed (2 positive, 1 mixed, 2 neutral), with high materiality in OXY (8/10) and VLO (8/10). Insider activity absent across filings; no capital allocation (dividends/buybacks), M&A, or ratios detailed. Portfolio-level pattern: 40% of filings highlight debt transactions, suggesting sector-wide deleveraging or refinancing ahead of volatility. Actionable implication: Near-term catalysts around Mar 9-19 settlements could support share prices for OXY/VLO.

4 high priority 1 medium 5 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 09, 2026

Across 50 SEC filings from diverse sectors mislabeled under S&P 500 Financials stream, dominant themes include mixed financial performance with robust revenue growth in 10/18 companies reporting YoY data (avg +120% e.g., SharpLink +666%, BETA +136%, ARS Pharma product +889% to $72.2M) offset by widening net losses in 12/15 (avg +80% deeper, driven by SG&A/R&D surges up 100-200% like ARS +186% opex). M&A and financing activity surges with 8 deals/placements (e.g., Aureus merger, Bunker Hill C$33.75M raise, Mission Produce S-4), signaling consolidation and capital infusion amid cash burns. Financials subset shines: Tri-County Bank NIM +44bps to 3.40%, NI +31% to $13.7M, ROE +164bps to 9.09%; Alexanders $235M asset sale for $147M gain. Capital allocation favors buybacks/dividends (GLDD $12M repurchases, W&T $0.01/sh div Mar 26, News Corp $1B program). Portfolio implications: Bullish on growth outliers pre-catalysts (international approvals, mergers closing Q2-Q3 2026), bearish on expense bloat; watch SPAC extensions/mergers for dilution risks.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 09, 2026

Across 19 filings in the S&P 500 Technology stream (broadly including telecom/IT-adjacent), a dominant theme is neutral proxy solicitations and additional materials for upcoming shareholder meetings, particularly in municipal funds and telecom (e.g., Nuveen urging FOR votes by March 19, 2026; Western Asset and Shenandoah meetings in April), signaling routine governance but potential M&A quorum risks. Financial reporters show mixed period trends: revenue declines averaging -7.6% YoY (RideNow -4.7% Q4/-10.5% FY; CMCT implied softer leasing) offset by EBITDA/FFO resilience (RideNow Q4 +340.9% to $9.7M, FY +40.4%; CMCT FFO improved from $(8.7M) to $(7.1M)). SPAC activity highlights tech upside with dMY Squared boosting PIPE to $111.86M via amendments and new investors, contrasting TETUF's 99.5% YoY asset plunge from redemptions. Positive debt maneuvers like Optimum's $1.657B fiber securitization refinancing at ~5.6-5.9% (vs prior 5.625%) bolster telecom balance sheets, while exec changes (Planet Fitness interim CFO, Lyell permanent CFO, Sun COO) are seamless with reaffirmed guidance. Portfolio-level, 3/5 financial filers exhibit EBITDA gains despite topline weakness, no insider trades noted, and capital allocation leans defensive (redemptions, asset sales); implications favor monitoring March-April catalysts for merger/SPAC votes amid neutral sentiment (12/19 neutral).

16 high priority 3 medium 19 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 09, 2026

Across 15 NASDAQ-100 related filings dated March 9, 2026, dominant themes include urgent proxy solicitations for Nuveen Municipal funds (4/15 filings) pushing for merger approvals by March 19, signaling consolidation in muni high-income space; positive financing and regulatory milestones in telecom/mining (Optimum's $1.657B securitization, TMC's NOAA compliance); mixed REIT results at CMCT with wider Q4 net loss but FFO improvement and $31.2M asset sale; deteriorating SPAC metrics at TETUF with 99.5% YoY asset drop; and executive appointments at Lyell and Sun Communities. Period-over-period trends show deterioration in key metrics like CMCT office leasing down 420bp YoY same-store and TETUF trust assets down 99.6% YoY from redemptions, contrasting with Optimum's debt repayment and CMCT's 19% total NOI growth. Portfolio-level patterns reveal neutral-to-positive sentiment in 10/15 filings, with high materiality events clustering around capital events and governance (proxies, redemptions), implying near-term catalysts from March-April shareholder meetings. Market implications favor monitoring muni fund mergers for arb opportunities and telecom strength amid fiber investments, while flagging SPAC liquidation risks.

11 high priority 4 medium 15 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 09, 2026

Across 50 SEC filings from the USA Dow Jones 30 stream (March 9, 2026), overarching themes include robust M&A and financing activity (e.g., Aureus Greenway merger, multiple PIPEs/securitizations totaling $300M+), mixed earnings with strong revenue growth in travel/defense (avg +25% YoY in 6 reporters) offset by margin compression (avg -150bps in 8 companies) and widening losses in biotech (9/12 reporters). Period-over-period trends show revenue up 15-34% YoY in key Q4/FY2025 reports (Amex GBT +34%, Voyager Tech +24%, 908 Devices +18%), but net losses expanded in 70% of loss-reporting firms (e.g., enGene +21%, Voyager Therapeutics FY -84% wider), alongside positive capital raises extending runways into 2028 (Korro Bio $85M, enGene $149M). Critical developments: 5 mergers/acquisitions, 8 financings/offerings, impairments in 4 firms ($43M+ Universal Logistics), and reiterated/raised guidance in 4 (Amex GBT 19-21% growth, Voyager Tech 35-53%). Portfolio-level patterns reveal sector rotation potential—bullish travel/logistics vs bearish shipping/biotech losses—amid governance shifts (CEO changes, board resignations) signaling transition risks/opportunities. Implications: Favor growth acquirers/financed biotechs with catalysts, avoid impairment-heavy firms; alpha from pre-close M&A and Q1 2026 guidance beats.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 09, 2026

Across 50 diverse SEC filings labeled under S&P 500 Consumer Discretionary (though spanning energy, REITs, services, industrials, and CEFs), overarching themes reveal mixed financial performance with 7 key companies posting YoY revenue growth averaging +24% (e.g., FuelCell +61%, LifeMD +25%, GLDD +16.5%) offset by 6 declines averaging -9% (e.g., Franklin Street -10.8%, FreightCar -10%, Fluent -18% FY), alongside frequent leadership transitions and capital return initiatives. Margin trends show outliers like FreightCar (+260bps to 14.6%) and LifeMD gross margin to 87%, but compressions in W&T EBITDA (-15.6%) and Fluent Owned revenue (-44%). Critical developments include Bright Horizons' $600M buyback authorization, Franklin Street's dividend suspension amid occupancy drop to 68.9%, and debt paydowns (Amplify full repayment, GLDD long-term debt -15.6% to $378M). Portfolio-level patterns highlight cash strength (LifeMD $36.8M no debt, FuelCell $379.6M) contrasting FCF weakness (W&T to $1.5M, Amplify FY -$16.1M), with forward guidance mixed (FreightCar FY26 rev $500-550M up mid-point, LifeMD Q1 EBITDA loss $4-5M). Upcoming March-April 2026 shareholder meetings cluster as catalysts, while insider activity is sparse (minor Bunker Hill participation). Market implications favor selective longs in growth/margin expanders and shorts on deteriorating operations, prioritizing capital allocators amid volatility.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 09, 2026

In the S&P 500 Healthcare stream, biotechs like Editas, Spruce, Protagenic, Anixa, MBX, Pulse, and Dare demonstrate aggressive cost discipline with R&D expenses down 29-58% YoY across 5/7 firms, narrowing net losses 19-36% YoY and extending cash runways into 2027, amid pipeline advancements including Phase 3 initiations and BLA filings. Large providers Abbott, Humana, and UnitedHealth show capital raising via $1B+ debt issuances and conference participation, signaling M&A and strategic discussions. Positive clinical data highlights include Pulse's 74% nodule volume reduction (15-22 months post-treatment) and Editas' >90% LDL-C cuts preclinical. Cross-sector filings reveal bank profitability surges (e.g., Financial Institutions NI +170% YoY, ROAE 12.49%) and mixed retail/energy trends, but healthcare outliers shine with margin-neutral cost cuts vs. broader compression. Forward catalysts cluster mid-2026 (IND/BLA/Phase 3), positioning biotechs for alpha amid 4/37 mixed sentiment filings. Overall, healthcare portfolio trend: 6/10 key firms improved losses YoY despite revenue softness, implying resilient cash management but binary pipeline risks.

21 high priority 16 medium 37 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 06, 2026

Across 41 SEC filings dated March 6, 2026, primarily 8-Ks, 10-Ks, and proxies from diverse sectors mislabeled as Consumer Staples, overarching themes include FY2025 revenue declines in 6/12 reporting companies averaging -6% YoY (Krispy Kreme -8.6%, IMXI -8%, Mammoth -2.9%, ArcelorMittal -1.7%), widening net losses in biotechs (PMV +32% to $77.7M) offset by narrowing in services (Mammoth -65% to $63.8M via SG&A -83%), and active M&A (KEEMO control stake, Kratos $353M Orbit buy, Monroe-HRZN merger). Forward-looking catalysts shine with PMV NDA Q1 2027 (34% ORR), Clover GAAP profit 2026, Honeywell Aerospace spin Q3 2026, and Monroe pro forma NII rising to $1.24 by 2030. Capital allocation trends favor buybacks (Lakeland doubled to $60M) and debt for repurchases (O'Reilly $850M notes), but dilution risks loom from offerings (Modular $12M at premium) and conversions (Velo3D notes). Portfolio-level patterns reveal cash pressures (PMV cash -38% to $113M, runway Q2 2027) and litigation (Monroe suits), implying selective opportunities in clinical/M&A plays amid broader weakness. Sector implications point to turnaround potential via divestitures (Mammoth $150M cash, liquidity $157M) but vigilance on delistings (UAMY) and impairments (Krispy $356M goodwill).

25 high priority 16 medium 41 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 06, 2026

Across 87 filings from S&P 500 Industrials and adjacent sectors (heavily skewed to financials/banks at ~30%, biotechs/pharma ~15%, with true industrials like shipping, aerospace sparse), sentiment is mixed with 40% positive, 45% mixed, 15% negative; aggregate net income trends show 12/20 banks/financials up YoY (avg +35%, range 23-75%) driven by NII growth (avg +15%) and M&A, but offset by impairments/merger costs. Revenue growth strong in growth names (e.g., 25-39% YoY in Guidewire, Pattern Group, Granite Ridge) but margins compressed avg -100bps in 8/15 reporting cos amid higher opex/R&D. Key developments include M&A acceleration (Kratos Orbit $353M, Day One $2.5B acq at 68% premium, Honeywell Aerospace spin Q3 2026), proxy season ramp (20+ AGMs April 2026), and biotech catalysts (PMV NDA Q1 2027). Portfolio-level: Industrials show cap alloc stability (dividends flat/up), insider conviction low-visibility but positive CEO comp at Alphabet/Stanley; risks from credit deterioration (NPLs up in 4 banks) and cash burns (PMV -38% cash). Implications: Tactical longs in M&A banks/industrials, caution biotechs, watch Q1 earnings for NIM trends.

56 high priority 31 medium 87 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 06, 2026

In the S&P 500 Energy intelligence stream, Cheniere Energy's 8-K highlights a strategic Senior Notes offering due 2036 and 2056 for debt refinancing, capex, and growth opportunities, carrying high materiality (8/10) amid neutral sentiment. Howard Hughes Holdings' 8-K sets the 2026 AGM for June 4 with a record date of April 6, adjusting proposal deadlines to March 17 due to a >30-day shift from 2025, with low materiality (4/10) and neutral sentiment. No period-over-period comparisons (YoY/QoQ revenue, margins, or operational metrics) were disclosed across filings, limiting trend visibility. Absent insider trading activity, forward-looking guidance focuses on Cheniere's conditional debt raise and Howard Hughes' governance catalysts. Capital allocation leans toward Cheniere's debt-funded reinvestment vs. Howard Hughes' shareholder engagement timeline. Sector implications point to financing maneuvers supporting energy infrastructure amid no evident portfolio-level growth or compression patterns. Actionable focus: monitor Cheniere's offering execution for leverage shifts and Howard Hughes' proposal deadlines for governance risks.

1 high priority 1 medium 2 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 06, 2026

Across 347 filings from S&P 500 Financials and related entities, overarching themes include mixed financial performance with 12/25 10-Ks showing revenue growth averaging +25% YoY (e.g., Cohen & Co +454%, Chime +31%) but 8/25 reporting net losses widening (avg +40%, e.g., PMV Pharma +32%), margin compression in 7/15 cases (avg -150bps), and heavy M&A/SPAC activity (15 deals, e.g., Monroe Capital merger, Spring Valley fusion). Capital allocation favors dividends/buybacks in 9 firms (e.g., MarketWise +25% dividend, Cohen $0.95 special), while biotech/pharma (10 filings) highlight clinical progress amid cash burns (runway into 2027-2028). Insider activity shows low conviction with few buys but CEO transitions in 12 cases signaling potential shifts. Forward guidance mixed: 6 raises (e.g., MarketWise FY26 billings $300M), 4 cuts/lowers, building catalysts like AGMs (April) and earnings. Portfolio trends: Financials NIM stable/expanding in banks (e.g., Republic +20bps), but impairments/delisting risks in 8 small caps; relative outperformers like Cohen vs laggards like BP (-16% profit). Implications: Tactical buys in growth financials/M&A, caution on cash-burn biotechs.

237 high priority 110 medium 347 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 06, 2026

Across 22 filings in the USA S&P 500 Technology stream (though spanning finance, biotech, banks, and limited pure tech like Salesforce/NVIDIA), overarching themes include mixed financial performance with revenue/NII growth via M&A or clinical progress offset by rising expenses, NPAs, and dilutions; 7/22 showed YoY net income/loss improvements averaging 15% (e.g., biotechs narrowing losses 8-39%). Period-over-period trends highlight revenue acceleration in select names (IRADIMED +14% YoY, Camden NII +53% YoY) but portfolio declines (Oxford -3.4% YoY) and stable margins/NIM (IRADIMED gross 77% flat, banks ~4%). Insider activity limited to Form 4s (GENCO May25-Feb26 changes) and ownership updates (dMY to Mar6), signaling neutral conviction; capital allocation favors stable distributions/dividends (Oxford $0.105/share, Camden $0.42/qtr flat). Forward-looking catalysts cluster in biotechs (Immuneering 1H26 data, mid-2026 Ph3; Adial cash to H2 2026). Portfolio implications: Bullish turnaround in clinical biotechs, caution on banks' credit quality deterioration and dilutions; tech filings (Salesforce/NVIDIA) neutral with org/comp tweaks signaling continuity amid FY27 revenue focus.

16 high priority 6 medium 22 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 06, 2026

Across 19 NASDAQ-100 related SEC filings from March 6, 2026, dominant themes include mixed financial performances in regional banks driven by mergers (e.g., First Community's Hometown acquisition completed Jan 23, 2026; Camden's Northway boosting NII +53% YoY), biotech firms narrowing net losses amid clinical progress (Immuneering's 64% OS rate vs 35% benchmark, Adial's -39% net loss improvement), and neutral capital market activities like debt shelf registrations (CIBC $20B) and offerings (CPKC $1.2B). Period-over-period trends show revenue growth in select names (IRADIMED +14% YoY, Altimmune +105% YoY) but expense pressures (G&A up across biotechs, noninterest expenses +38% at Camden), with ROE dips in banks (First Community -0.39pp, Camden -0.40pp). Positive catalysts cluster in biotech (Immuneering Phase 3 mid-2026, expanded data 1H2026), while tech filings highlight executive compensation alignment (Alphabet CEO $355M package, NVIDIA FY2027 variable plan). Portfolio-level patterns reveal bank M&A fueling asset growth (+20% Camden, +2% Muncy) but credit quality mixed (Muncy NPAs +18%), suggesting sector rotation opportunities into biotechs with extended cash runways (Immuneering to 2029). Overall, filings signal cautious optimism with 7/19 mixed sentiment, emphasizing monitoring Q1 2026 catalysts for alpha.

14 high priority 5 medium 19 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 06, 2026

Across 110 SEC filings from diverse US-listed firms (despite DJIA 30 focus, spanning banks, biotechs, SPACs, energy, and fintech), sentiment is predominantly mixed/neutral (70+ filings), with 25% positive on growth catalysts like revenue surges (avg +20-30% YoY in standouts like Grab, Via, Republic Bancorp) and clinical progress, but offset by cash burns, impairments, and exec churn. Period-over-period trends reveal banking sector resilience (e.g., NIM expansions in Republic +20bps, Northrim +NII 20%) amid rising NPLs (e.g., Home Bancorp 1.25% vs 0.50%), while biotechs show widened losses (PMV +32% YoY) but pipeline advances; energy firms mixed with Mammoth liquidity up to $158M post-divestitures. Capital allocation leans conservative (shelf registrations, buybacks like Dave $70M repurchase, Harley 10b5-1 plan), with SPACs/M&A active (ReserveOne, Vine Hill). Forward-looking catalysts cluster in Q1-Q2 2026 (PMV NDA, Nuvve BESS ops, Aptiv spin-off), signaling near-term volatility but alpha in undervalued growth names. Portfolio implication: Rotate to banks with NIM tailwinds and biotechs with derisked trials, hedge delisting/Nasdaq risks in small caps.

75 high priority 35 medium 110 total filings